Hundreds of Detained Migrants Diagnosed With Mumps in 19 States

Mumps has swept through 57 immigration detention facilities in 19 states since September, according to the first U.S. government report on the outbreaks in the overloaded immigration system. The virus sickened 898 adult migrants and 33 detention center staffers, the Centers for Disease Control and Prevention said in its report Thursday. New cases continue as migrants are taken into custody or transferred between facilities, the report said. As of last week, outbreaks were happening in 15 facilities in seven states. In response to the report, Immigration and Customs Enforcement spokesman Bryan Cox said medical professionals at detention facilities screen all new detainees within 24 hours of their arrival to ensure that highly contagious diseases are not spread. Cox said some detainees come from countries where communicable diseases are less controlled than in the U.S. and carry with them the risk of spreading infection. The CDC report said more than 80% of patients were exposed while in custody. Mumps is a contagious virus that causes swollen glands, puffy cheeks, fever, headaches and, in severe cases, hearing loss and meningitis. In the U.S., vaccines have drastically reduced the number of mumps cases. Only a few hundred cases are reported most years, with periodic outbreaks involving colleges or other places where people are in close contact. In the migrant center outbreaks, at least 13 people were hospitalized, the CDC reported. A large portion of the cases have been in Te...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Immigration onetime Source Type: news

Related Links:

Publication date: Available online 22 September 2020Source: Heart &LungAuthor(s): Silvio A. Ñamendys-Silva
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
US drugmaker Johnson&Johnson says the vaccine could be available for use by early 2021 if proven safe, effective. In the next phase J&J will enroll up to 60,000 volunteers across three continents and study safety and efficacy of a single vaccine dose.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
Johnson&Johnson has advanced its one-shot COVID-19 vaccine into phase 3 testing. The National Institute of Allergy and Infectious Diseases describes this as the fourth candidate to reach this stage.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Infectious Diseases News Source Type: news
Unlike some of its competitors, Johnson&Johnson ’s vaccine does not need to be frozen and may require just one shot instead of two.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Johnson & your-feed-healthcare Drugs (Pharmaceuticals) Research Moderna Inc Pfizer Inc Source Type: news
Dr. Anthony S. Fauci and three other top U.S. health officials steering the government ’s virus response told senators that they would take a vaccine approved by the F.D.A. Johnson&Johnson announced that it plans to enroll 60,000 people in its Phase 3 vaccine trial.
Source: NYT Health - Category: Consumer Health News Tags: Coronavirus (2019-nCoV) Source Type: news
In this study, we compared the immunogenicity and protective efficacy of CMFO subunit vaccines against primary progressive TB in two different adjuvant systems: the MTO oil-in-water (O/W) emulsion composed of monophosphoryl lipid A (MPL), trehalose-6,60-dibehenate (TDB), and oil in water emulsion MF59 and the DMT liposome containing dimethyldioctadecylammonium bromide (DDA), monophosphoryl lipid A (MPL), and trehalose-6,60-dibehenate (TDB). Our results demonstrated that the DMT-adjuvanted CMFO could confer more significant protection against M. tuberculosis infection than the CMFO/MTO did in mice. In particular, the adjuva...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Publication date: Available online 21 September 2020Source: The LancetAuthor(s): Enrico Bucci, Konstantin Andreev, Anders Björkman, Raffaele Adolfo Calogero, Ernesto Carafoli, Piero Carninci, Paola Castagnoli, Andrea Cossarizza, Cristina Mussini, Philippe Guerin, Brian Lipworth, Gianluca Sbardella, Teresa Stocki, Loretta Tuosto, Christoffer van Tulleken, Antonella Viola
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 21 September 2020Source: The LancetAuthor(s): Denis Y Logunov, Inna V Dolzhikova, Amir I Tukhvatullin, Dmitry V Shcheblyakov
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: Available online 21 September 2020Source: The LancetAuthor(s): Malik Peiris, Gabriel M Leung
Source: The Lancet - Category: General Medicine Source Type: research
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com.  -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.
Source: Healthy Living - The Huffington Post - Category: Consumer Health News Source Type: news
More News: Centers for Disease Control and Prevention (CDC) | Children | Colleges | Government | Headache | Health | Health and Safety | International Medicine & Public Health | Legislation | Measles | Measles Vaccine | Medical Law | Men | Meningitis | Meningitis Vaccine | Mexico Health | Mumps | Mumps Vaccine | Outbreaks | Rubella | Rubella Vaccine | Tax | Vaccines